期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2010欧洲血液年会纪要

原文传递
导出
摘要 第15届欧洲血液学协会年会（European Hematology Association,EHA）于2010年6月10～13日在西班牙美丽城市巴塞罗那举办.本届年会共收到2 175篇论文,聚集了来自欧洲、美国、亚洲等全球各地血液病临床医生和学者,规模盛大,内容新颖,ASH/EHA联合座谈会专题讨论发展中国家血液肿瘤领域面临的考验和机遇,大会也延续以往的传统,着重讨论了血液病学在基础研究和临床质量等方面的最新进展.本文就大会亮点作一介绍.
作者 阎骅 沈志祥
机构地区 上海交通大学医学院附属瑞金医院血液科
出处 《国际输血及血液学杂志》 CAS 2010年第5期460-462,共3页 International Journal of Blood Transfusion and Hematology
关键词 血液学 年会 欧洲 临床医生 血液病学 发展中国家 巴塞罗那 血液肿瘤
分类号 R733 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Castagnetti F,Palandri F,Gugliotta G,et al.Long term outcome of 559 Ph+ chronic myeloid myeloid leukemia patients treated front-line with imatinib:5-year results of 3 independent studies of the GIMEMA CML Working Party.Haematologica,2010,95(suppl 2):54,abs.0134.
  • 2Russo D,Rosti G,Martinelli G,et al.Update of cytogenetic and molecular response in 88 elderly Ph+ chronic myeloid leukemia patients enrolled in the phase Ⅱ explorative study of intermittent imatinib (IM) treatment (INTERIM).Haematologica,2010,95(suppl.2):58,abs.0143.
  • 3Hochhaus A,Lobo C,Pasquini R,et al.Continued superiority of Nilotinib vs Imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP):ENESTND beyond 1 year.Haematologica,2010,95 (suppl.2):459,abs.1113.
  • 4Salles G,Catalano J,Feugier P,et al.Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy:Results of the PRIMA study.Haematologica,2010,95(suppl.2):229,abs.0557.
  • 5Kennedy D,Mwamburi M,Ranganathan G,et al.BendamustineRituximab combination treatment in relapsed NHL:Combined experience from two phase 2 trials and exploration of response predictors.Haematologica,2010,95(suppl.2):117,abs.0294.
  • 6Morgan G,Davies F,Gregory W,et al.Zoledronic acid (ZOL)prolongs time to first skeletal-related event (SRE) and survival versus clodronate in newly diagnosed multiple myeloma (MM):MRC Myeloma Ⅸ trial results.Zoledronic acid (ZOL)significantly increases progression-free survival (PFS) versus clodronate and may improve response rates in newly diagnosed multiple myeloma (MM):MRC Myeloma Ⅸ trial results.Haematologica,2010,95(suppl.2):232,abs.0562.
  • 7Hahn-Ast C,yon Lilienfeld-Toal M,van Heteren P,et al.Improved progression-free survival and overall survival with thalidomide maintenance therapy in multiple myeloma:a mtsanalysis of randomized trials in 2274 patients.Haematologica,2010,95(suppl.2):391,abs.0942.
  • 8Spins F,Montefusco V,Crippa C,et al.Lenalidomide induces long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines:In particular after allogeneic transplantation.Haematologica,2010,95 (suppl.2):153,abs.0380.
国际输血及血液学杂志
2010年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部